After the Closing Bell: OPES, JIH.U, WRLS
by Kristi Marvin on 2019-11-04 at 6:32pm

Today’s Monday Madness, in no particular order….


OPES ACQUISITION CORP. (OPES)

Opes Acquisition Corp. (OPES), filed a definitive proxy this evening filling in some of those blanks we’ve all been wondering about regarding their upcoming November 15th extension vote.  However, we now know that OPES will be asking for two additional months to extend to January 15, 2020.  Furthermore, the Sponsor will be contributing $0.0325 per share to the trust for shareholders who do not redeem.  There is a remaining question though, which is, why only a two month extension?  If you recall, Opes recently replaced most of their management and Board, so this is essentially a “fresh team”.  So, is it possible for this new team to announce and close a transaction by January 15, 2020?  Or do they already have something up their sleeve?  Two months is a very short window to announce and close, but it is still possible. We’ll have to wait until post-extension vote to find out.


JUNIPER INDUSTRIAL HOLDINGS, INC. (JIH.U)

Juniper Industrial Holdings, Inc. (JIH.U), filed a new S-1 this morning with some changes to their forthcoming IPO.  Namely, their previous time horizon of 24 months, plus an additional 3 months with a definitive agreement or LOI, has now been changed to just 24 months. Additionally, Juniper previously was able to remove up to $250,000 of interest per year to fund regulatory compliance requirements, but that has now also been removed.  In the current terms environment, an extra 3 months time without a contribution and the removal of interest from trust was probably a hard sell.  However, now that the terms have been revised, the runway should be clear for a pricing next week.  However, there is a slight possibility they IPO on Thursday.  Stay tuned.


PENSARE ACQUISITION CORP. (WRLS)

Pensare Acquisition Corp. (WRLS) filed their definitive proxy for their vote to extend their deadline to April 1, 2020.  This is so Pensare has additional time to close their combination with Computex.  The vote date is scheduled for November 26th, with a record date of October 30th and a redemption deadline of November 22nd.  Pensare will not be offering any contribution to trust for shareholders who do not redeem at the vote.  However, their current trust value is only $3.2 million, so this vote is mostly a formality.


 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved